INVENTIVA S.A.(PROM.)-01
Research INVENTIVA S.A.(PROM.)-01 (6IV) on Bullrun: market cap EUR 905.91M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker6IV
- ExchangeF
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 905.91M
- Financial periodFY2025
- RevenueEUR 4.48M
- Revenue growth-51.3%
- Net income-EUR 354.14M
- Free cash flow-EUR 105.13M
Valuation Snapshot
latest market cap is EUR 905.91M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 4.48M | -EUR 354.14M | -EUR 105.13M | n/a | -1.9 | EUR 99.31M | EUR 59.86M | -EUR 28.52M |
| FY2024 | EUR 9.20M | -EUR 184.21M | -EUR 86.26M | n/a | -3.08 | EUR 96.56M | EUR 54.33M | -EUR 106.65M |
| FY2023 | EUR 17.48M | -EUR 110.43M | -EUR 82.15M | n/a | -2.43 | EUR 26.92M | EUR 37.49M | -EUR 32.03M |
| FY2022 | EUR 12.18M | -EUR 54.27M | -EUR 45.49M | n/a | -1.31 | EUR 86.74M | EUR 34.52M | EUR 45.48M |
| FY2021 | EUR 4.19M | -EUR 49.64M | n/a | n/a | -1.27 | EUR 86.55M | EUR 8.84M | EUR 88.87M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-14 | EUR 905.91M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About INVENTIVA S.A.(PROM.)-01
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is INVENTIVA S.A.(PROM.)-01's market cap?
INVENTIVA S.A.(PROM.)-01's market capitalization is EUR 905.91M.
What does INVENTIVA S.A.(PROM.)-01 do?
Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. It develops Lanifibranor, a novel peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. The company also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis.